S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.37 (+1.62%)
AAPL   143.11 (+4.01%)
MSFT   260.15 (+3.01%)
FB   196.28 (+1.42%)
GOOGL   2,229.15 (+2.34%)
AMZN   2,152.65 (+0.04%)
TSLA   674.70 (+1.63%)
NVDA   169.00 (+1.23%)
BABA   87.50 (+0.82%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.82 (+2.56%)
DIS   105.50 (+3.01%)
AMC   11.58 (-3.74%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.47 (+0.60%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.37 (+1.62%)
AAPL   143.11 (+4.01%)
MSFT   260.15 (+3.01%)
FB   196.28 (+1.42%)
GOOGL   2,229.15 (+2.34%)
AMZN   2,152.65 (+0.04%)
TSLA   674.70 (+1.63%)
NVDA   169.00 (+1.23%)
BABA   87.50 (+0.82%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.82 (+2.56%)
DIS   105.50 (+3.01%)
AMC   11.58 (-3.74%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.47 (+0.60%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.37 (+1.62%)
AAPL   143.11 (+4.01%)
MSFT   260.15 (+3.01%)
FB   196.28 (+1.42%)
GOOGL   2,229.15 (+2.34%)
AMZN   2,152.65 (+0.04%)
TSLA   674.70 (+1.63%)
NVDA   169.00 (+1.23%)
BABA   87.50 (+0.82%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.82 (+2.56%)
DIS   105.50 (+3.01%)
AMC   11.58 (-3.74%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.47 (+0.60%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.37 (+1.62%)
AAPL   143.11 (+4.01%)
MSFT   260.15 (+3.01%)
FB   196.28 (+1.42%)
GOOGL   2,229.15 (+2.34%)
AMZN   2,152.65 (+0.04%)
TSLA   674.70 (+1.63%)
NVDA   169.00 (+1.23%)
BABA   87.50 (+0.82%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.82 (+2.56%)
DIS   105.50 (+3.01%)
AMC   11.58 (-3.74%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.47 (+0.60%)
NASDAQ:OPNT

Opiant Pharmaceuticals Earnings Date, Estimates, & History

$13.79
-0.22 (-1.57%)
(As of 05/23/2022 03:59 PM ET)
Add
Compare
Today's Range
$13.60
$13.79
50-Day Range
$10.12
$26.18
52-Week Range
$7.34
$37.71
Volume
822 shs
Average Volume
91,507 shs
Market Capitalization
$70.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.65

Earnings Summary

Upcoming
Earnings Date
Aug. 4Estimated
Actual EPS
(May. 10)
-$2.43 Missed By -$1.68
Consensus EPS
(May. 10)
-$0.75
Last Year's Q2 EPS
(5/11/2021)
-$0.66
Skip Charts & View Estimated and Actual Earnings Data

Opiant Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Opiant Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.20)($0.20)($0.20)
Q2 20222($1.48)($0.85)($1.17)
Q3 20222($1.55)($0.79)($1.17)
Q4 20222($1.73)($0.93)($1.33)
FY 20227($4.96)($2.77)($3.87)

OPNT Earnings Information

Opiant Pharmaceuticals last released its quarterly earnings results on May 10th, 2022. The technology company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $1.68. The company had revenue of $4.47 million for the quarter, compared to analysts' expectations of $7.13 million. Opiant Pharmaceuticals has generated ($1.45) earnings per share over the last year (($1.45) diluted earnings per share). Earnings for Opiant Pharmaceuticals are expected to grow in the coming year, from ($6.21) to ($0.74) per share. Opiant Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off prior year's report dates.

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/4/2022
(Estimated)
        
5/10/2022Q1 2022($0.75)($2.43)($1.68)($2.43)$7.13 million$4.47 million    
3/15/2022Q4 2021$0.10$0.11+$0.01$0.11$13.68 million$13.80 million    
11/11/20219/30/2021$0.15$0.56+$0.41$0.56$12.45 million$16.34 million    
8/5/20216/30/2021($0.28)$0.31+$0.59$0.31$8.01 million$11.26 million  
5/11/20213/31/2021($0.71)($0.66)+$0.05($0.66)$5.29 million$6.39 million  
3/4/202112/31/2020$0.12($0.16)($0.28)($0.16)$9.30 million$9.92 million  
11/12/2020Q3($0.19)$0.15+$0.34$0.15$7.94 million$9.11 million  
8/6/2020Q2 2020($0.31)($0.05)+$0.26($0.05)$6.47 million$6.31 million  
5/12/2020Q1($0.19)($0.40)($0.21)($0.40)$4.63 million$4.28 million  
3/4/202012/31/2019$0.31$0.20($0.11)$0.20$7.70 million$7.67 million  
11/12/20199/30/2019$0.10$1.97+$1.87($1.97)$5.73 million$20.64 million  
8/8/2019Q2 2019($0.55)$0.31+$0.86$0.31$3.91 million$6.78 million
5/9/20193/31/2019($0.88)($0.44)+$0.44($0.44)$1.90 million$5.44 million  
3/21/20197/31/2018($0.08)($0.37)($0.29)($0.37)$5.20 million$4.76 million  
11/7/2018Q3($0.11)($0.32)($0.21)($0.32)$4.70 million$4.37 million
8/9/2018Q2 2018($1.07)($0.52)+$0.55($0.52)$2.10 million$3.15 million
5/8/2018Q1 2018($0.29)($3.68)($3.39)($3.68)$2.00 million$1.70 million
12/4/2017Q1 2018($1.19)($2.77)($1.58)($2.77)$0.02 million
10/13/2017Q4 2017($0.87)($0.17)+$0.70($0.17)$3.77 million
6/14/2017Q3 2017($0.82)($1.55)($0.73)($1.55)$0.02 million
3/16/2017Q2 2017($0.85)$4.91+$5.76$4.91$13.54 million
12/16/2016Q1 2017($1.14)($0.30)+$0.84($0.30)$0.70 million$1.12 million
10/31/2016Q4 2016($0.52)($0.52)($0.52)$0.10 million$0.31 million
6/8/2016Q3 2016$0.15+$0.15$0.15$2.61 million
3/15/2016Q2 2016$1.52+$1.52$1.52$6.86 million
8/7/2012$0.19$0.21+$0.02
5/14/2012$0.20$0.21+$0.01
2/7/2012$0.29$0.26($0.03)  
11/9/2011$0.24$0.24
8/2/2011$0.15$0.21+$0.06
5/9/2011$0.19$0.20+$0.01  
1/27/2011$0.16$0.23+$0.07
(Earnings results data provided by Zacks Investment Research)












Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings Frequently Asked Questions

When is Opiant Pharmaceuticals's earnings date?

Opiant Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 4th, 2022 based off last year's report dates. Learn more on OPNT's earnings history.

Did Opiant Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Opiant Pharmaceuticals (NASDAQ:OPNT) missed the analysts' consensus estimate of ($0.75) by $1.68 with a reported earnings per share (EPS) of ($2.43). Learn more on analysts' earnings estimate vs. OPNT's actual earnings.

How can I listen to Opiant Pharmaceuticals's earnings conference call?

The conference call for Opiant Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Opiant Pharmaceuticals's conference call transcript?

The conference call transcript for Opiant Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Opiant Pharmaceuticals generate each year?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a recorded annual revenue of $47.78 million.

How much profit does Opiant Pharmaceuticals generate each year?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a recorded net income of $3.01 million. OPNT has generated -$1.45 earnings per share over the last four quarters.

What is Opiant Pharmaceuticals's EPS forecast for next year?

Opiant Pharmaceuticals's earnings are expected to grow from ($6.21) per share to ($0.74) per share in the next year.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.